Using a blood marker to predict breast cancer relapse
Part of Cancer, Skin clinical trials.
This study looks at a blood test (for SEMA4C) to see whether it can help predict the risk of breast cancer coming back (relapse). It may help doctors monitor patients more closely if the marker matches relapse risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of breast cancer confirmed by biopsy or surgery.
- You can understand the study and sign written consent.
- You are able to provide blood/serum samples that meet the study’s lab requirements.
- You agree to attend follow-up visits during the study.
- You have no history of other cancers before this breast cancer diagnosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether specific “surveillance” markers (measured from blood and bone marrow) can help predict if breast cancer comes back after standard treatments. It may help doctors monitor you more accurately and earlier if recurrence risk is high.
This study looks for tiny bits of cancer DNA in your blood after breast cancer surgery. A blood test called NGS may help doctors find early signs of cancer coming back, and you would give samples and have checkups for 3 years.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This study builds a “genome atlas” to better predict the chance that breast cancer will come back. It asks participants to share medical information and provide blood and tumor tissue samples, including samples kept in paraffin.
This trial uses a blood test to look for tiny bits of tumor DNA after treatment. If found, participants receive new drug combinations to try to prevent cancer from returning.
This trial looks at how certain proteins (ER, PR, and HER2/neu) on breast cancer cells change when the cancer comes back in the same spot. Knowing this could help doctors choose the best treatment for your recurrence.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.